keyword
MENU ▼
Read by QxMD icon Read
search

rHGH

keyword
https://www.readbyqxmd.com/read/27926952/growth-hormone-treatment-increases-plasma-irisin-concentration-in-patients-with-turner-syndrome
#1
B Wikiera, K Zawadzka, Ł Łaczmański, N Słoka, M Bolanowski, A Basiak, A Noczyńska, J Daroszewski
Irisin (Ir) deficiency may be a contributing factor in metabolic disease. This study aimed to investigate the effect of supraphysiological doses of recombinant human growth hormone (rhGH) on Ir plasma concentration in relation to metabolic disorders, including obesity and other components of metabolic syndrome. We studied 36 girls with Turner syndrome (mean age 8.2 years) treated with rhGH (0.05 mg/kg/day). Anthropometric data and fasting blood levels [e. g., Ir, insulin, glucose, glycated hemoglobin (HbA1c), IGF-1, IGFBP-3, cholesterol, insulin resistance (HOMA-IR), and β-cell function (HOMA-β)] were analyzed prior to and following rhGH therapy [mean (SD) follow-up of 1...
December 7, 2016: Hormone and Metabolic Research, Hormon- und Stoffwechselforschung, Hormones et Métabolisme
https://www.readbyqxmd.com/read/27914605/simultaneous-detection-of-recombinant-growth-hormones-in-equine-plasma-by-liquid-chromatography-high-resolution-tandem-mass-spectrometry-for-doping-control
#2
Kin-Sing Wong, George H M Chan, Emmie N M Ho, Terence S M Wan
Growth hormone (GH), or somatotropin, is a protein that may enhance physical performance and facilitate growth and wound healing. For this reason, growth hormones and their recombinant analogues are prohibited in human sports by the World Anti-Doping Agency (WADA) and in horseracing under Article 6 of the International Agreement on Breeding, Racing and Wagering published by the International Federation of Horse Racing Authorities (IFHA). Identifying the illicit use of GHs in both human athletes and racehorses is challenging, especially when differentiating between endogenous and exogenous GHs, and between analogues of GH from different species...
November 21, 2016: Journal of Chromatography. A
https://www.readbyqxmd.com/read/27803832/a-child-with-local-lipohypertrophy-following-recombinant-human-growth-hormone-administration
#3
Ilan J N Koppen, Roel Bakx, Chris C de Kruiff, A S Paul van Trotsenburg
Local lipohypertrophy due to recombinant human growth hormone (rhGH) administration is a rare phenomenon. Here, we report a case of an 11-year-old girl who presented with a paraumbilical swelling, approximately one year after the start of rhGH treatment for short stature due to the presumed diagnosis of partial growth hormone insensitivity. Ultrasound imaging revealed an asymmetric distribution of subcutaneous fat tissue at the rhGH administration site, indicating local lipohypertrophy. After sparing her routine injection site and alternating other sites, the swelling disappeared within 6 months...
2016: Case Reports in Pediatrics
https://www.readbyqxmd.com/read/27746341/growth-hormone-is-protective-against-acute-methadone-induced-toxicity-by-modulating-the-nmda-receptor-complex
#4
Erik Nylander, Alfhild Grönbladh, Sofia Zelleroth, Shanti Diwakarla, Fred Nyberg, Mathias Hallberg
Human growth hormone (GH) displays promising protective effects in the central nervous system after damage caused by various insults. Current evidence suggests that these effects may involve N-methyl-d-aspartate (NMDA) receptor function, a receptor that also is believed to play a role in opioid-induced neurotoxicity. The aims of the present study were to examine the acute toxic effects of methadone, an opioid receptor agonist and NMDA receptor antagonist, as well as to evaluate the protective properties of recombinant human GH (rhGH) on methadone-induced toxicity...
December 17, 2016: Neuroscience
https://www.readbyqxmd.com/read/27717280/evaluation-of-fibronectin-1-in-one-dried-blood-spot-and-in-urine-after-rhgh-treatment
#5
P Ferro, R Ventura, C Pérez-Mañá, M Farré, J Segura
Since the appearance of recombinant human growth hormone (rhGH) in the 80's, its expansion and acquisition through the black market has increased, so the detection of its abuse continues to be a challenge at present. New biomarkers that are more reliable and sensitive, allowing a larger detection window, are still needed. In this line, Fibronectin 1 (FN1) has been proposed as potential genetic and protein biomarker of rhGH abuse in peripheral blood lymphocytes, serum and plasma. However, logistic problems associated with current blood collection in sports drug testing points towards potential new alternative matrices that could be good candidates to be evaluated...
October 7, 2016: Drug Testing and Analysis
https://www.readbyqxmd.com/read/27659551/-somatotropic-axis-and-molecular-markers-of-mineral-metabolism-in-children-undergoing-chronic-peritoneal-dialysis
#6
María Luisa Ceballos Osorio, Francisco Cano Schuffeneger
: Growth failure is one of the most relevant complications in children with chronic kidney disease (CKD). Among others, growth hormone (GH) resistance and bone mineral disorders have been identified as the most important causes of growth retardation. OBJECTIVES: 1. To characterize bone mineral metabolism and growth hormone bio-markers in CKD children treated with chronic peritoneal dialysis (PD). 2. To evaluate height change with rhGH treatment. PATIENTS AND METHOD: A longitudinal 12-month follow-up in prepuberal PD children...
September 19, 2016: Revista Chilena de Pediatría
https://www.readbyqxmd.com/read/27627580/functional-changes-after-recombinant-human-growth-hormone-replacement-in-patients-with-chronic-traumatic-brain-injury-and-abnormal-growth-hormone-secretion
#7
Kurt A Mossberg, William J Durham, Dennis J Zgaljardic, Charles R Gilkison, Christopher P Danesi, Melinda Sheffield-Moore, Brent E Masel, Randall J Urban
We explored the effects of recombinant human growth hormone (rhGH) replacement on physical and cognitive functioning in subjects with a moderate-to-severe traumatic brain injury (TBI) with abnormal growth hormone (GH) secretion. Fifteen individuals who sustained a TBI at least 12 months prior to study enrollment were identified as having abnormal GH secretion by glucagon stimulation testing (maximum GH response less than 8 ng/mL). Peak cardiorespiratory capacity, body composition, and muscle force testing were assessed at baseline and one year after rhGH replacement...
October 13, 2016: Journal of Neurotrauma
https://www.readbyqxmd.com/read/27507700/determination-of-recent-growth-hormone-abuse-using-a-single-dried-blood-spot
#8
Gemma Reverter-Branchat, Jaume Bosch, Jessica Vall, Magí Farré, Esther Papaseit, Simona Pichini, Jordi Segura
BACKGROUND: Although it is being increasingly applied, blood collection for drug testing in sport presents some logistic issues that complicate full applicability on a large scale. The use of dried blood spots (DBS) could benefit compliant blood testing considerably owing to its simplicity, minimal invasiveness, analyte stability, and reduced costs. The aim of this study was to evaluate the applicability of DBS to the methodology approved by the World Anti-Doping Agency (WADA) for detection of doping by recombinant human growth hormone (rhGH) in serum...
October 2016: Clinical Chemistry
https://www.readbyqxmd.com/read/27469300/endogenous-signal-peptides-in-recombinant-protein-production-by-pichia-pastoris-from-in-silico-analysis-to-fermentation
#9
Aslan Massahi, Pınar Çalık
For extracellular recombinant protein production, the efficiency of five endogenous secretion signal peptides (SPs) of Pichia pastoris, SP13 (MLSTILNIFILLLFIQASLQ), SP23 (MKILSALLLLFTLAFA), SP24 (MKVSTTKFLAVFLLVRLVCA), SP26 (MWSLFISGLLIFYPLVLG), SP34 (MRPVLSLLLLLASSVLA), selected based on their D-score which quantifies the signal peptide-ness of a given sequence segment, was investigated using recombinant human growth hormone (rhGH) as the model protein. The expression was conducted under glyceraldehyde-3-phosphate dehydrogenase promoter (PGAP)...
November 7, 2016: Journal of Theoretical Biology
https://www.readbyqxmd.com/read/27459425/high-purity-recombinant-human-growth-hormone-rhgh-expression-in-escherichia-coli-under-phoa-promoter
#10
Hao Song, Jingxin Jiang, Xuedong Wang, Jianguo Zhang
Recombinant human growth hormone (rhGH) is an important protein for human growth and is in high demand in clinics. Hence, it is necessary to develop an efficient fermentation process to produce highly pure rhGH. In this study, rhGH was expressed in Escherichia coli under alkaline phosphatase (phoA) promoter. The cultivation conditions for high expression level and purity of rhGH were investigated. The best initial phosphate concentration for rhGH expression, out of the 4 levels of initial phosphate concentration tests performed, was 12...
July 26, 2016: Bioengineered
https://www.readbyqxmd.com/read/27459301/a-rare-variant-of-turner-syndrome-in-four-sequential-generations-effect-of-the-interplay-of-growth-hormone-treatment-and-estrogens-on-body-proportion
#11
Judith Stoklasova, Jana Kaprova, Marie Trkova, Vera Nedomova, Dana Zemkova, Jana Matyskova, Ondrej Soucek, Zdenek Sumnik, Jan Lebl
BACKGROUND: Terminal Xp deletion leads to SHOX haploinsufficiency, and when it exceeds Xp22.33 it causes a variant of Turner syndrome (TS) in which gonadal function is preserved and short stature constitutes the major clinical feature. CASE REPORT: We present a family with vertical transmission of TS that affected six women in four sequential generations. The karyotype was defined as a combination of terminal Xp deletion and terminal Xq duplication: 46,X,rec(X)inv(p21...
July 27, 2016: Hormone Research in Pædiatrics
https://www.readbyqxmd.com/read/27457999/targeting-gh-1-splicing-as-a-novel-pharmacological-strategy-for-growth-hormone-deficiency-type-ii
#12
Maria Consolata Miletta, Christa E Flück, Primus-E Mullis
Isolated growth hormone deficiency type II (IGHD II) is a rare genetic splicing disorder characterized by reduced growth hormone (GH) secretion and short stature. It is mainly caused by autosomal dominant-negative mutations within the growth hormone gene (GH-1) which results in missplicing at the mRNA level and the subsequent loss of exon 3, producing the 17.5-kDa GH isoform: a mutant and inactive GH protein that reduces the stability and the secretion of the 22-kDa GH isoform, the main biologically active GH form...
July 22, 2016: Biochemical Pharmacology
https://www.readbyqxmd.com/read/27437620/growth-hormone-receptor-isoforms-and-fracture-risk-in-adult-onset-growth-hormone-deficient-patients
#13
M Mormando, S Chiloiro, A Bianchi, A Giampietro, F Angelini, L Tartaglione, L Nasto, D Milardi, A M Formenti, A Giustina, L De Marinis
INTRODUCTION: Growth hormone deficiency is considered the most important factor determining skeletal fragility in hypopituitary patients. Osteoblasts and chondrocytes express growth hormone (GH) receptor. Two GH receptor isoforms (GHRi) have been identified: they differ for the presence/absence of a protein fragment encoded by exon 3 of GHR gene. Consequently, three genotypes were identified: carriers of both the full-length proteins (flfl-GHR), carriers of one full-length protein and one deleted protein (fld3-GHR) and carriers of both deleted proteins (d3d3-GHR)...
November 2016: Clinical Endocrinology
https://www.readbyqxmd.com/read/27417288/low-dose-growth-hormone-therapy-reduces-inflammation-in-hiv-infected-patients-a-randomized-placebo-controlled-study
#14
Johanne Bjerre Lindboe, Anne Langkilde, Jesper Eugen-Olsen, Birgitte R Hansen, Thomas H Haupt, Janne Petersen, Ove Andersen
BACKGROUND: Combination antiretroviral therapy (cART) has drastically increased the life expectancy of HIV-infected patients. However, HIV-infected patients exhibit increased inflammation and 33-58% exhibit a characteristic fat re-distribution termed HIV-associated lipodystrophy syndrome (HALS). Recombinant human growth hormone (rhGH) has been tested as treatment of HALS. Low-dose rhGH therapy improves thymopoiesis and fat distribution in HIV-infected patients and appears to be well tolerated...
November 2016: Infectious Diseases
https://www.readbyqxmd.com/read/27384621/-ghrd3-polymorphism-of-growth-hormone-receptor-gen-in-peruvian-children-with-idiopathic-short-stature
#15
Carlos Del Águila, César Ortiz, Mirtha Yarlequé, Candy Bellido, Miguel Zaldivar, Juan Falen
OBJECTIVES: To describe the standardization of molecular detection and frequency of a growth hormone receptor gene deleted for exon three (GHRd3) polymorphism in a population of Peruvian children with idiopathic short stature. MATERIALS AND METHODS: Peripheral blood samples were used from patients (N=64) who were diagnosed with idiopathic short stature and were treated at the endocrinology unit of the National Institute of Child Health in Peru The amplification of exon 3 was carried out using G1, G2, and G3 primers by optimizing PCR conditions, such as annealing temperature and magnesium concentration...
March 2016: Revista Peruana de Medicina Experimental y Salud Pública
https://www.readbyqxmd.com/read/27382409/recombinant-human-growth-hormone-and-insulin-like-growth-factor-1-do-not-affect-mitochondrial-derived-highly-reactive-oxygen-species-production-in-peripheral-blood-mononuclear-cells-under-conditions-of-substrate-saturation-in-vitro
#16
James Keane, Lotti Tajouri, Bon Gray
BACKGROUND: The purpose of this study was to investigate the mitochondrial effects exerted by physiological and supra-physiological concentrations of recombinant human growth hormone (rhGH) and recombinant insulin-like growth factor-1 (rIGF-1) under conditions of substrate saturation in peripheral blood mononuclear cells (PBMCs). METHODS: PBMCs from healthy male subjects were treated with either rhGH, at concentrations of 0.5, 5 and 50 μg/L, or rIGF-1 at concentrations of 100, 300 and 500 μg/L for 4 h...
2016: Nutrition & Metabolism
https://www.readbyqxmd.com/read/27355624/height-outcome-of-recombinant-human-growth-hormone-treatment-in-achondroplasia-children-a-meta-analysis
#17
Mario Miccoli, Silvano Bertelloni, Francesco Massart
BACKGROUND/AIMS: Although recombinant human growth hormone (rhGH) is not approved to treat short stature of achondroplasia (ACH), some studies suggested growth improvement during short-term rhGH treatment. METHODS: A meta-analysis of rhGH therapy efficacy in ACH children was performed. RESULTS: From 12 English-language studies, 558 (54.0% males) rhGH-treated ACH children were enrolled. Administration of rhGH (median dosage 0.21 mg/kg/ week; range 0...
2016: Hormone Research in Pædiatrics
https://www.readbyqxmd.com/read/27293538/seven-years-of-follow-up-of-trabecular-bone-score-bone-mineral-density-body-composition-and-quality-of-life-in-adults-with-growth-hormone-deficiency-treated-with-rhgh-replacement-in-a-single-center
#18
Gonzalo Allo Miguel, Alicia Serraclara Plá, Myriam Lorena Partida Muñoz, Guillermo Martínez Díaz-Guerra, Federico Hawkins
BACKGROUND: Adult growth hormone deficiency (AGHD) is characterized by impaired physical activity, diminished quality of life (QoL), weight and fat mass gain, decreased muscle mass and decreased bone mineral density (BMD). The aim of this study was to evaluate the effects of long-term treatment (7 years) with recombinant human growth hormone (rhGH) on metabolic parameters, body composition (BC), BMD, bone microarchitecture and QoL. PATIENTS AND METHODS: In this prospective study, BMD and BC were assessed by dual-energy X-ray absorptiometry (DXA)...
June 2016: Therapeutic Advances in Endocrinology and Metabolism
https://www.readbyqxmd.com/read/27292870/mortality-and-cancer-incidence-among-patients-treated-with-recombinant-growth-hormone-during-childhood-in-israel
#19
Carmit Libruder, Orit Blumenfeld, Rita Dichtiar, Zvi Laron, Zvi Zadik, Tamy Shohat, Arnon Afek
CONTEXT: The inconclusive evidence regarding long term safety of rhGH therapy underlines the need for long-term large-scale cohorts. OBJECTIVE: To assess long term mortality and cancer incidence among patients treated with rhGH during childhood in Israel. DESIGN: A population-based cohort study. SETTING: Data were retrieved from a national register established in 1988. Mortality data from the national population register were available through December 31st, 2014...
June 13, 2016: Clinical Endocrinology
https://www.readbyqxmd.com/read/27286443/physiological-growth-hormone-replacement-and-rate-of-recurrence-of-craniopharyngioma-the-genentech-national-cooperative-growth-study
#20
Timothy R Smith, David J Cote, John A Jane, Edward R Laws
OBJECTIVE The object of this study was to establish recurrence rates in patients with craniopharyngioma postoperatively treated with recombinant human growth hormone (rhGH) as a basis for determining the risk of rhGH therapy in the development of recurrent tumor. METHODS The study included 739 pediatric patients with craniopharyngioma who were naïve to GH upon entering the Genentech National Cooperative Growth Study (NCGS) for treatment. Reoperation for tumor recurrence was documented as an adverse event. Cox proportional-hazards regression models were developed for time to recurrence, using age as the outcome and enrollment date as the predictor...
October 2016: Journal of Neurosurgery. Pediatrics
keyword
keyword
10705
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"